REG - GENinCode PLC - CARDIO inCode-Score® US study publication

GenincodeAnnouncement

04/04/2024 10:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240404:nRSD3406Ja&default-theme=true

RNS Number : 3406J  GENinCode PLC  04 April 2024

GENinCode Plc

("GENinCode" or the "Company")

 

CARDIO inCode-Score® clinical publication on polygenic risk of Coronary Heart
Disease

US study publication in the American Journal of Preventive Cardiology

 

Oxford, UK. GENinCode Plc (AIM: GENI), the polygenics company focused on the
prevention of cardiovascular disease and ovarian cancer, announces today the
publication by the American Journal of Preventive Cardiology of a study on
'Polygenic Risk and Incident Heart Disease in a large multiethnic cohort'.(1)

 

The Kaiser Permanente Division of Research study investigated more than 63,000
adult individuals with no history of Coronary Heart Disease (CHD) who are part
of the Kaiser Permanente Northern California Genetic Epidemiology Resource in
Adult Health and Aging (GERA) multi-ethnic cohort. The GERA cohort followed
the membership over an average of 14 years, using CARDIO inCode-Score® to
assess the polygenic risk of CHD and future incidence of risk of CHD.

 

The study found that CARDIO inCode-Score® can identify individuals at the
highest risk of CHD. These individuals should then be prioritised for
lifestyle advice and where appropriate therapeutic intervention as they will
benefit the most. Previous data with CARDIO inCode-Score® has shown that, for
individuals with a high genetic risk, a favourable lifestyle is associated
with a 52% lower rate of CHD compared with an unfavourable lifestyle. CHD
'event' includes: non-fatal AMI, angina or coronary atherosclerosis, coronary
revascularisation procedures (coronary by-pass or percutaneous intervention)
or CHD death. The study underlines the need for 'polygenic risk score'
lifetime risk assessment in conjunction with traditional clinical risk
assessment to optimise preventive care strategies to lower the future risk of
CHD.

 

Polygenic risk assessment can be undertaken in younger people, before
conventional clinical risk factors (such as high blood pressure, diabetes
etc.) have developed and can be combined with conventional risk scoring in
older people. In this way clinicians can better identify those most likely to
benefit from lifestyle and therapeutic intervention.

 

Other recently announced news

GENinCode is commencing its commercialisation of CARDIO inCode-Score® (or
CIC-SCORE) with leading healthcare institutions in the United States to
provide an improved estimation of an individual's risk of heart attack over
their lifetime. CIC-Score is being delivered from the GENinCode CLIA and CAP
approved laboratory in Irvine, California.

 

The Company filed its CIC-Score 'De Novo' medical device submission with the
FDA at the end of last year. The Company continues to progress its submission
for FDA approval of the CIC-SCORE medical device to enable the scale up and
processing by labs across the United States.

 

Kaiser Permanente will be presenting new data on CARDIO inCode-Score® at the
European Society of Cardiology, Preventive Cardiology conference on 25 - 27
April 2024 in Athens, Greece. This presentation will focus on low-density
lipoprotein cholesterol (LDL-C) and polygenic risk for the incidence of
coronary heart disease.

 

In the UK around 7.6m people live with heart and circulatory disease, which
causes 25% of all deaths annually. CVD can be reduced by identifying and
treating individuals at risk, and the NHS 10 Year Plan (2019) sets out to
address CVD prevention.

 

Jamal Rana MD, Chief of Cardiology at Kaiser Permanente, Oakland said: "It was
an immense effort from our  Kaiser Permanente Northern California team and we
are delighted with the study outcome. These first publication results show the
inclusion of the CARDIO inCode-Score® polygenic risk score can improve the
identification of primary prevention individuals who would benefit from more
intensive treatment."

 

Matthew Walls, CEO of GENinCode PLC said: "We are delighted with the American
Journal of Preventive Cardiology publication and the results from this study.
The publication represents the first major clinical publication showing the
clinical utility of the CARDIO inCode-Score® (polygenic risk score) in a
large multi-ethnic US cohort to identify individuals at high genetic risk of
coronary heart disease thereby enabling targeted, personalised treatment and a
breakthrough in preventive care."

 

(1) https://www.sciencedirect.com/science/article/pii/S2666667724000291
(https://www.sciencedirect.com/science/article/pii/S2666667724000291)

 

For more information visit www.genincode.com (http://www.genincode.com)

Enquiries:

 

 GENinCode Plc                      www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO

 Cavendish Capital Markets Limited  Tel: +44 (0)20 7397 8900
 Giles Balleny / Dan Hodkinson (Corporate Finance)
 Nigel Birks (Corporate Broking) / Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited                                                  Tel: 020 7933 8780 or genincode@walbrookpr.com

                                                                    (mailto:genincode@walbrookpr.com)
 Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventative care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to predict
cardiovascular disease.

 

About CARDIO inCode-Score® (CIC-SCORE)

CIC-SCORE is a first in class in-vitro diagnostic test used to assess an
individuals genetic risk of CHD. The test is based on published clinical
evidence amassed over 15 years which, combined with traditional clinical risk
factors, provides a comprehensive risk assessment of CHD for use in primary
preventive care. GENinCode labs process patient DNA samples and deliver the
CARDIO inCode-Score® test results to physicians via an online cloud based
algorithmic (AI) reporting system ('SITAB').

 

CIC-SCORE also addresses the well-recognised need for improvement in the
cardiovascular disease (CVD) standard of care across ethnicities where
individuals from certain racial and ethnic groups face higher risks of CVD.
The CIC-SCORE test provides an improved estimation of an individual's risk of
heart attack over their lifetime, particularly within a 10-year period post
testing when combined with traditional clinical risk assessment. The CIC-SCORE
polygenic risk score enables a major improvement in patient CVD risk
assessment, preventive care and personalised treatment to reduce the incidence
of major adverse cardiovascular events (MACE), such as heart attack.

 

About Kaiser Permanente:

Founded in 1945, Kaiser Permanente is one of the United States largest
not-for-profit health plans, serving more than 9 million members, with
headquarters in Oakland, California.

It comprises: Kaiser Foundation Hospitals and their subsidiaries Kaiser
Foundation Health Plan, Inc. The Permanente Medical Groups.

Kaiser Permanente physicians are responsible for medical decisions. The
Permanente Medical Groups, which provide care for Kaiser Permanente members,
continuously develop and refine medical practices to help ensure that care is
delivered in the most efficient and effective manner possible.

About Cardiovascular Disease (CVD):

Heart and circulatory disease also known as cardiovascular disease (CVD) is
the leading cause of death globally, taking an estimated 17.9 million lives
each year, with Coronary Heart Disease (CHD) representing the leading
cause of death for men, women, and people of most racial and ethnic groups
in the United States. CVD is a group of disorders of the heart and blood
vessels that include coronary heart disease, cerebrovascular disease,
rheumatic heart disease and other conditions. More than four out of five CVD
deaths are due to heart attacks and strokes, and one third of these deaths
occur prematurely in people under 70 years of age. By 2030 the global cost
of CVD is set to rise from approximately US$863 billion in 2010 to US$1,044
billion and is both a major health issue and global economic burden.

 

Cardiovascular disease, causes a quarter of all deaths in the UK and is the
largest cause of premature mortality in deprived areas and is the single
biggest area where the NHS can save lives over the next 10 years. CVD is
largely preventable, through lifestyle changes and a combination of public
health and action on smoking and tobacco addiction, obesity, tackling alcohol
misuse and food reformulation.

 

The most important behavioural risk factors of heart disease and stroke are
unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol.
The effects of behavioural risk factors may show up in individuals as raised
blood pressure, raised blood glucose, raised blood lipids, and overweight and
obesity. These "intermediate risks factors" can be measured in primary care
facilities and indicate an increased risk of heart attack, stroke, heart
failure and other complications.

 

Identifying those at highest risk of CVDs and ensuring they receive
appropriate treatment can prevent premature deaths. Access to noncommunicable
disease medicines and basic health technologies in all primary health care
facilities is essential to ensure that those in need receive treatment and
counselling.

 

The current standard of care for assessing cardiovascular risk is primarily
based on traditional clinical risk factors such as age, sex, smoking, body
mass, blood pressure and cholesterol levels from which individuals are
categorised as being at low, moderate or high risk of a CVD event. This
categorisation is imperfect as CVD events frequently occur in those thought to
be at low or moderate risk. The size of the populations at low or moderate
risk are much larger than those at high or very high risk so whilst the
relative risk of a CVD event may be small, the absolute number of CVD events
in low and moderate risk populations is much greater than the number of events
in higher risk categories.  It is clear that the earlier in life preventative
measures can be put in place the lower the future risk.

 

Clinicians have for many years recognised the importance of prior CVD events
within the families of their patients because genetic factors contribute to
the development of atherosclerosis and a patient's family history has become a
surrogate for their inherited genetic risk. In recent years, with the advances
of genomics, it has proved possible to add genetic profiling to conventional
CVD risk factors, the combination of the two (genetics and conventional
clinical risk factors) enhancing the predictive capability of patient risk
thereby resulting in a personalised and preventative approach to CVD.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFIFSASFISIIS